S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Elon Bets Big On Controversial Energy Tech: "This Is Bigger Than AI" (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Elon Did It Again: This Could be Bigger than Tesla (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:NRIX

Nurix Therapeutics (NRIX) Stock Forecast, Price & News

$7.86
-0.28 (-3.44%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.78
$8.31
50-Day Range
$7.86
$9.74
52-Week Range
$7.78
$15.09
Volume
288,274 shs
Average Volume
388,230 shs
Market Capitalization
$378.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.44

Nurix Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
249.2% Upside
$27.44 Price Target
Short Interest
Bearish
14.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.24mentions of Nurix Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$43,898 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.55) to ($3.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

796th out of 972 stocks

Pharmaceutical Preparations Industry

378th out of 449 stocks


NRIX stock logo

About Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX Price History

NRIX Stock News Headlines

Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
What 4 Analyst Ratings Have To Say About Nurix Therapeutics
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
SVB Securities Remains a Buy on Nurix Therapeutics (NRIX)
See More Headlines
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Company Calendar

Last Earnings
7/13/2023
Today
10/01/2023
Next Earnings (Estimated)
10/05/2023
Fiscal Year End
11/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRIX
Fax
N/A
Employees
297
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.44
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+249.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-180,360,000.00
Net Margins
-258.37%
Pretax Margin
-258.37%

Debt

Sales & Book Value

Annual Sales
$38.63 million
Book Value
$6.44 per share

Miscellaneous

Free Float
44,730,000
Market Cap
$378.85 million
Optionable
Not Optionable
Beta
1.63
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Arthur T. Sands M.D. (Age 61)
    Ph.D., CEO, Pres & Director
    Comp: $910.98k
  • Mr. Johannes Van Houte (Age 57)
    Chief Financial Officer
    Comp: $650.74k
  • Dr. Gwenn M. Hansen Ph.D. (Age 52)
    Chief Scientific Officer
    Comp: $661.19k
  • Dr. John Kuriyan Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Michael Rapé Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Arthur Weiss M.D.
    Ph.D., Founder & Member of Scientific Advisory Board
  • Rita Kwong
    Sr. Accounting Mang.
  • Dr. Christine Ring J.D. (Age 58)
    Ph.D., Gen. Counsel & Sec.
  • Mr. Eric C. Schlezinger J.D. (Age 56)
    Chief People Officer
  • Dr. Jason Kantor Ph.D.
    Exec. VP of Fin. & Bus. Strategy













NRIX Stock - Frequently Asked Questions

Should I buy or sell Nurix Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NRIX shares.
View NRIX analyst ratings
or view top-rated stocks.

What is Nurix Therapeutics' stock price forecast for 2023?

9 brokerages have issued 1-year price objectives for Nurix Therapeutics' shares. Their NRIX share price forecasts range from $11.00 to $36.00. On average, they predict the company's share price to reach $27.44 in the next twelve months. This suggests a possible upside of 249.2% from the stock's current price.
View analysts price targets for NRIX
or view top-rated stocks among Wall Street analysts.

How have NRIX shares performed in 2023?

Nurix Therapeutics' stock was trading at $10.98 at the beginning of the year. Since then, NRIX shares have decreased by 28.4% and is now trading at $7.86.
View the best growth stocks for 2023 here
.

When is Nurix Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 5th 2023.
View our NRIX earnings forecast
.

How were Nurix Therapeutics' earnings last quarter?

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its earnings results on Thursday, July, 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. The company had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Nurix Therapeutics had a negative net margin of 258.37% and a negative trailing twelve-month return on equity of 53.36%.

What ETF holds Nurix Therapeutics' stock ?

ARK Genomic Revolution ETF holds 2,333,922 shares of NRIX stock, representing 0.94% of its portfolio.

What other stocks do shareholders of Nurix Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR).

When did Nurix Therapeutics IPO?

(NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

What is Nurix Therapeutics' stock symbol?

Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX."

How do I buy shares of Nurix Therapeutics?

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nurix Therapeutics' stock price today?

One share of NRIX stock can currently be purchased for approximately $7.86.

How much money does Nurix Therapeutics make?

Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $378.85 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How many employees does Nurix Therapeutics have?

The company employs 297 workers across the globe.

How can I contact Nurix Therapeutics?

The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com.

This page (NASDAQ:NRIX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -